Drugs / CAN1012
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07620496 | Jul 2026 → Jul 2031 expected | — | Providence Health & Services | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07408856 | May 2026 → May 2030 expected | ductal breast carcinoma in situ, lobular breast carcinoma in situ | Providence Health & Services | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05580991 | Sep 2022 → Jun 2025 overdue | neoplasm | Canwell Biotech Limited | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04987112 | Jan 2022 → Dec 2024 | metastatic malignant neoplasm | CanWell Pharma Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06410703 | Jun 2024 → May 2025 | neoplasm | Canwell Biotech Limited | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAN1012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05580991 ↗ |
| Action | Activate | “Selective TLR7 agonist” NCT04987112 ↗ |
| Route | Other | “CAN1012 IT injection” NCT04987112 ↗ |
| Target | TLR7 | “Selective TLR7 agonist” NCT04987112 ↗ |